G protein-coupled receptors (GPCRs) represent the largest protein family encoded by the human genome. Located on the cell membrane, they transduce extracellular signals into key...
G protein-coupled receptors (GPCRs) represent the largest protein family encoded by the human genome. Located on the cell membrane, they transduce extracellular signals into key...
GPCRs with mAb or peptide-based therapeutics might have a great therapeutic potential in a variety of diseases, including cancer, inflammatory disorders, neurological and ...
GPCR-targeted MTDLs have shown potentials in treating complex diseases and have become desirable targets for developing multi-target-directed ligands (MTDLs) because of ...
G protein-coupled receptors (GPCRs) represent important drug targets, as they regulate pivotal physiological processes and they have proved to be readily druggable.
Ackyee employs Deep Learning and Blockchain technology to create GPCRMIDAS, GPCROmics and GPCRMTDL , drug discovery platforms collaborating with YVBioMedical and YVLabs as well as strategic partners (Contract Research Organizations (CRO) and University Research Labs in US, Hong Kong and Europe).
Ackyee will focus on developing partnerships with pharmaceutical companies and Biotech companies providing Computational Biology and Chemistry Consulting Services.
Ackyee scientific team created GPCRMIDAs, GPCRomics and GPCRMTDL platforms for the purpose of integrating systems biology, medicinal chemistry, biophysics, deep learning and blockchain technology to fine-tune proposed compounds and address challenging problems across the drug discovery life cycle of G-protein-coupled receptors (GPCR’s) Drug Design and Discovery. It also serves to predict the structure of proteins, scan through databases of potential molecules to find some that best fit a particular biological target in order to cure different oncological, neurological and metabolic disorders.
Molecular Identification Design and Structure
G protein-coupled receptors (GPCRs) represent the largest protein family encoded by the human genome. Located on the cell membrane, they transduce extracellular signals into key physiological effects. GPCR structural biology range from classes A, B, C, and F with small-molecule as allosteric modulators. GPCRMIDAS is a proprietary AI-Enabled Drug Discovery platform that incorporates Deep Learning and Blockchain technology to focus on GPCR-targeted Small Molecules
Computational Biologics Discovery
GPCRs with mAb or peptide-based therapeutics might have a great therapeutic potential in a variety of diseases, including cancer, inflammatory disorders, neurological and metabolic diseases GPCRomics is a proprietary AI-Enabled Drug Discovery platform that incorporates Deep Learning and Blockchain technology to focus on GPCR-targeted biologics
Multi-Target Directed Ligands
GPCR-targeted MTDLs have shown potentials in treating complex diseases and have become desirable targets for developing multi-target-directed ligands (MTDLs) because of their crucial roles in the pathophysiology of various human diseases and the accessibility of druggable sites at the cell surface. GPCRMTDL is a proprietary AI-Enabled Drug Discovery platform that incorporates Deep Learning and Blockchain technology
So far, we have few drugs in pipelines that target either Neurological, Metabolic or Oncological GPCRs to combat various life-threatening diseases.
These are subtype selective small molecules that focused on targeting allosteric sites of neurological GPCRs as a mean to develop allosteric modulators to combat neurodegenerative diseases.
These ligands interact with both the orthosteric and allosteric site and utilizes their ability to introduce specific beneficial therapeutic effects for neurological disorders like psychosis and schizophrenia.
These compounds are highly specific to metabolic GPCRs which utilizes Glucose-stimulated insulin secretion (GSIS) pathway that eventually helps to regulate the activity of numerous neurotransmitters, hormones and paracrine factors.
These compounds bind with the orthosteric or allosteric sites of a subfamily of oncological GPCR membrane proteins which has promising role in cancer prevention, metastasis and resistance.
At Ackyee, our multi-faceted approach to building value starts from our outstanding AI-Enabled Drug Discovery platform technology, our stellar team and a growing proprietary pipeline of novel drug candidates.
Oxia Bioscience is a business unit of Ackyee with the mission of building a pipeline of small molecule compounds that bind with the orthosteric or allosteric sites of a subfamily of oncological GPCR membrane proteins which has promising role in cancer prevention, metastasis and resistance.
Xudiera is a business unit of Ackyee with the mission of building a pipeline of small molecules that interact with both orthosteric and allosteric site and utilizes their ability to introduce specific beneficial therapeutic effects for neurological disorders like psychosis and schizophrenia.
Zymetics is a business unit of Ackyee with the mission of developing a pipeline of small molecules highly specific to metabolic GPCRs that utilizes Glucose-stimulated insulin secretion (GSIS) pathway which eventually helps to regulate the activity of numerous neurotransmitters, hormones and paracrine factors.
During our journey to find new potent and effective Drugs against GPCRs, we have established number of collaborations or partnerships with Research organizations, Biotech/pharmaceutical companies and academic collaborations.
Ackyee growing portfolio of emerging joint venture companies headquartered in Asia will focus on GPCR Target discovery in CNS, Metabolic and Oncology diseases.
Ackyee Scientific team that is responsible for product development collaborates with Wuxi Apptec who provides Scientific is a Clinical Research Organization (CRO) with a focus of providing Trial Design, Statistical Analysis & Consulting, and Data Management of GPCR Target identification, validation and more.
Ackyee Scientific team collaborates with Università degli Studi dell'Aa for.
We are not a team because we work together, we are a team because we respect, trust and care for each other.
Interim
Interim
Research Scientist
Research Scientist
Scientific Advisor
Clinical Advisor
Advisor -Drug Discovery Platform
Director Platform Development
Director Platform Development